公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2023 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer | Im, S-A; Gennari, A; Park, Y H; Kim, J H; Jiang, Z-F; Gupta, S; Fadjari, T H; Tamura, K; Mastura, M Y; Abesamis-Tiambeng, M L T; Lim, E H; CHING-HUNG LIN ; Sookprasert, A; Parinyanitikul, N; Tseng, L-M; Lee, S-C; Caguioa, P; Singh, M; Naito, Y; Hukom, R A; Smruti, B K; Wang, S-S; Kim, S B; Lee, K-H; Ahn, H K; Peters, S; Kim, T W; Yoshino, T; Pentheroudakis, G; Curigliano, G; Harbeck, N | ESMO open | 4 | 1 | |
2018 | A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer | WEI-WU CHEN ; Yeh D.-C.; Chao T.-Y.; CHING-HUNG LIN ; Chow L.W.-C.; DWANG-YING CHANG ; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG ; YEN-SHEN LU ; Taiwan Breast Cancer Consortium | Japanese Journal of Clinical Oncology | 4 | 3 | |
2008 | A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline | RUEY-LONG HONG ; CHING-HUNG LIN ; Chao T.-Y.; Kao W.-Y.; Wang C.-H.; Hsieh R.K.; Hwang W.-S. | Cancer Chemotherapy and Pharmacology | 9 | 7 | |
2017 | Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen | I-CHUN CHEN ; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; CHING-HUNG LIN ; Wei-Wu Chen T.; ANN-LII CHENG ; YEN-SHEN LU | Scientific Reports | 23 | 20 | |
2013 | Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas | Wu P.-F.; Huang W.-C.; CHIH-HSIN YANG ; YEN-SHEN LU ; JIN-YUAN SHIH ; SHANG-GIN WU ; CHING-HUNG LIN ; ANN-LII CHENG | Journal of Neuro-Oncology | 8 | 5 | |
2015 | A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis | Wu P.-F.; CHING-HUNG LIN ; CHING-HUA KUO ; WEI-WU CHEN ; Yeh D.-C.; Liao H.-W.; Huang S.-M.; ANN-LII CHENG ; YEN-SHEN LU | BMC Cancer | 48 | 36 | |
2016 | A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer | BANG-BIN CHEN ; YEN-SHEN LU ; CHING-HUNG LIN ; WEI-WU CHEN ; Wu P.-F.; CHAO-YU HSU ; CHIH-WEI YU ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | BMC Cancer | 20 | 17 | |
2023 | Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer | WEI-WU CHEN ; Hsiao, Wen; Dai, Ming-Shen; CHING-HUNG LIN ; DWANG-YING CHANG ; I-CHUN CHEN ; MING-YANG WANG ; Chang, Shu-Han; Huang, Shu-Min; ANN-LII CHENG ; Wu, Ko-Wen; Tan, Kien Thiam; YEN-SHEN LU | Breast cancer research and treatment | 0 | 0 | |
2017 | Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer | SUNG-HSIN KUO ; Yang S.-Y.; You S.-L.; HUANG-CHUN LIEN ; CHING-HUNG LIN ; PO-HAN LIN ; CHIUN-SHENG HUANG | Oncotarget | 35 | 30 | |
2010 | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | YU-YUN SHAO ; KUAN-TING KUO ; Hu F.-C.; YEN-SHEN LU ; CHIUN-SHENG HUANG ; JAU-YU LIAU ; Lee W.-C.; CHIUN HSU ; WEN-HUNG KUO ; KING-JEN CHANG ; CHING-HUNG LIN ; ANN-LII CHENG | Japanese Journal of Clinical Oncology | 28 | 24 | |
2015 | Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart | Chang C.; CHING-HUNG LIN ; ANN-LII CHENG ; Medeiros L.J.; Chang K.-C. | Histopathology | 22 | 23 | |
2011 | Prognostic molecular markers in Women aged 35 years or younger with breast cancer: Is there a difference from the older patients? | CHING-HUNG LIN ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; KUAN-TING KUO ; Wang C.-C.; You S.-L.; PO-HAN LIN ; DWANG-YING CHANG ; WEN-HUNG KUO ; KING-JEN CHANG ; ANN-LII CHENG | Journal of Clinical Pathology | 8 | 8 | |
2014 | Quantification of target analytes in various biofluids using a postcolumn infused-internal standard method combined with matrix normalization factors in liquid chromatography-electrospray ionization mass spectrometry | Liao H.-W.; Tsai I.-L.; GUAN-YUAN CHEN ; YEN-SHEN LU ; CHING-HUNG LIN ; CHING-HUA KUO | Journal of Chromatography A | 12 | 12 | |
2018 | Rebuttal comments on “Glucocorticoids in breast cancer treatment: Real benefit or selection bias?” | CHING-HUNG LIN ; Tang C.-H. | Breast Cancer Research and Treatment | 0 | 0 | |
2020 | Response to Sung, Rosenberg, and Yang | CHING-HUNG LIN ; Yap Y.S.; Lee K.-H.; Yeo W.; Ueno T.; Li H.; Huang S.-M.; YEN-SHEN LU | Journal of the National Cancer Institute | 0 | 0 | |
2022 | Risk Factors for Female Breast Cancer: A Population Cohort Study | Wang Y.-C.; CHING-HUNG LIN ; Huang S.-P.; Chen M.; Lee T.-S. | Cancers | 4 | 5 | |
2011 | Separation and detection of rare cells in a microfluidic disk via negative selection | Chen, C.-L.; Chen, K.-C.; Pan, Y.-C.; Lee, T.-P.; Hsiung, L.-C.; Lin, C.-M.; Chen, C.-Y.; CHING-HUNG LIN ; BOR-LUEN CHIANG ; ANDREW WO | Lab on a Chip | 66 | 64 | |
2010 | Separation and detection of rare cells via multistage magnetic gradient in a microfluidic disk | Chen C.-L.; Chen K.-C.; Pan Y.-C.; Lee T.-P.; Yang C.-W.; Hsiung L.-C.; Lin C.-M.; Chen C.-Y.; CHING-HUNG LIN ; BOR-LUEN CHIANG ; Wo A.M. | 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010, MicroTAS 2010 | 0 | | |
2016 | Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? | WEI-WU CHEN ; CHING-HUNG LIN ; CHIUN-SHENG HUANG | Translational Cancer Research | 1 | 1 | |
2014 | A spatiotemporally defined in vitro microenvironment for controllable signal delivery and drug screening | Kuo, C.-T.; Liu, H.-K.; Huang, G.-S.; Chang, C.-H.; Chen, C.-L.; Chen, K.-C.; RUBY YUN-JU HUANG ; CHING-HUNG LIN ; Lee, H.; CHIUN-SHENG HUANG ; ANDREW WO | Analyst | 16 | 14 | |